Review Article
CODEN (USA): IJPLCP

ISSN: 0976-7126
Parvin *et al.,* 15(1):4-13, 2024

International Journal of Pharmacy & Life Sciences
Open Access to Researcher

Intervention and Treatment of HIV/AIDS through Nanotechnology

Saheen Parvin[1*], Priya Bindal[2], Himani Tiwari[3] and Kaushal Kishor Chandrul[4]

1, Student of B. Pharm. 4th Year; 2, Assistant Professor; 3, HOD; 4, Principal

Department of Pharmacy, Mewar University, Gangrar Chittorgarh, (R.J.) - India

Article info

Received: 17/12/23

Revised: 17/01/2024

Accepted: 23/01/2024

© *IJPLS*

www.ijplsjournal.com

Abstract
Currently, there is no cure or vaccine for HIV/AIDS. Antiretroviral drugs have improved treatment but have drawbacks such as lifelong usage, side effects, and ineffectiveness against drug-resistant strains. However, nanotechnology shows promise in revolutionizing HIV/AIDS treatment. It can enhance antiretroviral therapy, gene therapy, immunotherapy, microbicides, and vaccines. Nanoparticles can be delivered through inhalation, injection, or ingestion, and have shown effectiveness against the virus in laboratory tests. This technology has the potential to significantly improve prevention and therapy for HIV/AIDS.

Keywords: Nanomedicine, nanoparticles, vaccines, AIDS, antiretroviral therapy, gene therapy, HIV, immunotherapy, and microbicide.

Introduction

The use of antiretroviral drugs has increased the lifespan of HIV/AIDS patients, but there is still no cure or vaccine for the virus. Nanoparticles (NPs) are a promising technology for preventing and treating HIV/AIDS. NPs are solid particles with sizes less than 200 nm, and certain types have therapeutic capabilities. NPs can enter the body through oral intake, direct injection, or inhalation, and have shown potential in advancing prevention and treatment. Nanotechnology can also improve current therapy and develop new approaches like immunotherapy and gene therapy. In a clinical trial, gene transfer using cell-delivered ribozyme showed promising results in reducing viral load and preserving the immune system in HIV-infected individuals.

***Corresponding Author**

Approaches of nanotechnology in treatment of HIV/AIDS

Nanotechnology-based platforms can distribute antiviral drugs in the body, extending their half-lives and improving drug adherence. Nanoscale delivery systems can control the distribution of drugs in diverse tissues due to their small size, making them promise for HIV treatment. A recent study tested nanosuspensions of Rilpivirine on mice and dogs, showing sustained release for 3 months in dogs and 3 weeks in mice, compared to a 38-hour half-life for free medication. This demonstrates the potential of nanoscale medicine delivery to increase adherence and decrease dosing frequency.

Current treatment for HIV / AIDS

HAART, the most advanced HIV/AIDS treatment, involves giving patients multiple antiretroviral medications at once. Despite its success, challenges remain, such as therapy failure due to low patient compliance. Resistance to certain treatment combinations can also occur. Genetic diversity and mutation of HIV-1 contribute to drug resistance. Individualized therapy and resistance testing are being used to address this. Adverse effects, such as heart disease and cancer, can be caused by both HIV infection and the medications used in HAART. Removing the virus completely from the body is currently impossible because it resides in latent reservoirs. Macrophages, in addition to being reservoirs, contribute to the creation of mutant viral genotypes. These reservoirs are found in various areas of the body, and removing the virus from these areas is essential for effective long-term treatment. Developing new strategies for non-toxic and consistent dosing coverage is crucial.



Nanotechnology for HIV / AIDS treatment

Nanotechnology is revolutionizing drug delivery, particularly benefiting cancer patients. It enables more effective administration of drugs that are not water-soluble, targeted delivery to specific cells or tissues, and distribution of macromolecules within cells. Similar advantages can be applied to antiviral drugs using nanotechnology-based platforms. Controlled-release methods can extend drug half-lives and improve medication adherence. Nanoscale techniques enhance drug distribution in different tissues. Nanocarriers like liposomes and dendrimers enhance cellular uptake and release in tissues. Active targeting using macrophage receptors improves uptake and localization of antiretroviral drugs. These advancements show the potential of nanotechnology in delivering antiretroviral drugs to target cells and HIV reservoirs. Further clinical studies are needed to explore these technologies.

Nanotechnology as therapeutic agents

Nanomaterials, including dendrimers and nanoparticles like gold and silver, have healing qualities and can hinder HIV replication by interfering with viral assembly. In vitro studies show their potential to stop HIV replication, using drugs based on the structure of the HIV capsid. [56,57,58,59]

Gene therapy for HIV/AIDS

Efforts to find new HIV/AIDS treatment options are being complemented by the enhancement of existing antiretroviral medications. Gene therapy, a potential alternative, involves inserting a gene into a cell to prevent viral infection or replication. Various nucleic acid and protein-based compounds, including DNA, siRNA, RNA decoys, ribozymes, fusion inhibitors, and zinc-finger nucleases, can be used to inhibit viral proliferation. Clinical trials using viral vectors as delivery methods for gene therapy are currently underway, such as a collaboration between Benitec Ltd. and City of Hope. UCLA researchers have also demonstrated the safety and benefits of cell-derived gene transfer in HIV-infected individuals. However, challenges with viral vectors have prompted research into nonviral vectors, particularly nanotechnology platforms. RNA interference (RNAi), a Nobel Prize-winning discovery, has gained attention for its potential therapeutic applications in age-related macular degeneration, respiratory syncytial virus, and HIV/AIDS. Specifically, siRNA can silence genes involved in viral entry and replication.

Immunotherapy for HIV/AIDS

Various therapy approaches for HIV/AIDS either target the virus itself or the host cell. Immunotherapy aims to alter the immune system's response to HIV, focusing on normalizing CD8+ cytotoxic T-cell responses and restoring immunological function. The reduction of CD4+ T cells in HIV infection leads to severe immunosuppression. The use of immune responses to regulate HIV and restore the immune system's regular operation is gaining attention for effective treatment. Immunotherapy involves the administration of immunologic formulations, such as cytokines or antigens, to treat HIV-positive individuals. Delivery of these formulations to dendritic cells can generate cellular and humoral immunity. Clinical trials using immunotherapeutic techniques have shown limited therapeutic benefits, partly due to the challenges of ex vivo generation of autologous dendritic cells. Nanotechnology-based immunotherapy offers opportunities for precise delivery of immunomodulatory factors to dendritic cells in vivo. Polymeric systems and nanoparticles have been studied for the targeting and delivery of substances with immunotherapeutic potential to dendritic cells. The Derma Vir patch, a nanotechnology-based immunotherapy, has shown promise in Phase II clinical trials for HIV/AIDS treatment. Further research in nanotechnology-based immunotherapy is encouraged



Nanotechnology for HIV / AIDS prevention

The search for a safe and effective HIV/AIDS vaccine has been difficult due to the diversity of viral strains and the ability of the virus to evade the immune system. Protein antigens must be broken down and loaded into MHC molecules for presentation to T cells, but it is challenging to deliver exogenous antigens to antigen-presenting cells (APCs). Nanoparticles have the potential to act as adjuvants and delivery systems for vaccines, as they can be targeted to APCs and provide controlled release of antigens. They can also be administered orally or topically, targeting mucosal immunity. Liposomes and polymers have been investigated for the delivery of HIV/AIDS vaccines and have shown promising results in generating immune responses. Cationic lipids, oil-in-water emulsions, and nanoparticles have been used to enhance the immune response to HIV antigens. The use of CpG oligonucleotides and dendritic cells as vaccine targets has also been explored. Overall, while the development of nanoparticle-based HIV/AIDS vaccines is still in its early stages, progress has been made and these delivery systems show potential for improving immune responses.

Implication of nanoparticles in HIV/AIDS therapy

Advancements in treating diseases have led to a decrease in the number of medications patients need to take daily. Nanoparticles with polymers have been developed to deliver ART therapies effectively and long-term to the body and brain cells. Antiretroviral drug administration has greatly improved with the use of nanotechnology, increasing compliance rates. Nanoparticles loaded with ART drugs target HIV-loving infection sites, providing targeted and long-lasting drug delivery. Nanoparticles can also bypass the blood-brain barrier and successfully administer anti-HIV medications. Developing vaccines and utilizing nanotechnology, such as genetic treatment and immunotherapy, are promising methods to combat illnesses.

Future aspects of nanoparticle-based HIV/AIDS therapy

Nanoparticles have shown promise in the treatment of viral agents, particularly in HIV/AIDS prevention and treatment. By modifying nanoparticles, they can be enhanced to improve traditional antiviral properties. This has great potential for biological and biomedical studies in clinical settings. Nanotechnology advancements offer therapeutic potential for universal technologies, overcoming barriers and reducing toxicity. Further research is needed on multi-functionalization for simultaneous drug delivery and imaging, as well as multiplexing for a wider range of diseases. Understanding the interaction between nanoparticles and the immune system is crucial for the development of nano vaccines and immunostimulatory drugs. Additionally, studying the potential deleterious effects and toxicity of nanoparticles is important. Addressing viral evolution and understanding the versatility of nanoparticles is important for effective treatment of infectious diseases.

Conclusions

Recent advancements in nanotechnology have shown potential for improving HIV/AIDS treatment and prevention. Nanoparticles (NPs) are being used to transport antiretroviral drugs to target locations, such as macrophages and brain tissues, where traditional medicine is ineffective. Different types of NPs, including fullerenes, inorganic nanoparticles, and dendrimers, have demonstrated anti-HIV activity. Nanotechnology platforms can enhance treatment choices and improve patient adherence through regulated and extended drug release. Targeted nanoparticles have been used to attack macrophages, a key HIV viral reservoir. Additionally, nanotechnology is being explored for gene therapy, immunotherapy, and vaccine development. While nanotherapeutics may increase treatment costs, the benefits of improved patient adherence and viral reservoir eradication could outweigh the higher expense. Nanotechnology-enabled vaccines and microbicides could be cost-effective solutions for combating the global HIV/AIDS pandemic. Ongoing investment in nanotechnology research will likely continue to have a positive impact on medicine and the fight against HIV/AIDS.

References

1.Blattner W, Gallo RC, Temin HM. HIV causes AIDS. Science. 1988;241(4865):515–516.
2.Gallo RC. Historical essay. The early years of HIV/AIDS. Science. 2002;298(5599):1728– 1730.
3.Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med. 2003;349(24):2283–2285.
4.Montagnier L. Historical essay. A history of HIV discovery. Science. 2002;298(5599):1727–1728.
5.Furin JJ, Behforouz HL, Shin SS, et al. Expanding global HIV treatment: Case studies from the field. Ann NY Acad Sci. 2008; 1136:12–20.
6.Merson MH. The HIV-AIDS pandemic at 25 – the global response. N Engl J Med. 2006;354(23):2414–2417.
7.Joint United Nations Programme on HIV/AIDS. Joint United Nations Programme on HIV/AIDS. Geneva, Switzerland: 2008. Report on the global HIV/AIDS epidemic.
8.Rodriguez-Monguio R, Seoane-Vazquez E. Patent life of antiretroviral drugs approved inthe US from 1987 to 2007. AIDS Care. 2009:1–9.
9.Lang L. FDA grants tentative approval for 75th generic antiretroviral drug. Gastroenterology. 2009;136(1):5.
10.Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–19.
11.Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323(5919):1304–1307.
12.Richman DD. HIV chemotherapy. Nature. 2001;410(6831):995–1001.
13.Ledford H. Merck's HIV vaccine flop brings vectors under closer scrutiny. Nat Biotechnol. 2008;26(1):3–4.
14.Ledford H. HIV vaccine developers battle on, despite high-profile failures. Nat Biotechnol. 2008;26(6):591–592.
15.Uberla K. HIV vaccine development in the aftermath of the step study: Re-focus on occult HIV infection? PLoS Pathog. 2008;4(8): e1000114.
16.Cohen J. Aids research. Microbicide fails to protect against HIV. Science. 2008;319(5866):1026–1027.
17.Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides? Science. 2008;321(5888):532–534.
18.Farokhzad OC. Nanotechnology for drug delivery: The perfect partnership. Expert OpinDrug Deliv. 2008;5(9):927–929.

19.Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
20.Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171.
21.Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007; 9:257–288.
22.Heath JR, Davis ME. Nanotechnology, and cancer. Ann Rev Med. 2008; 59:251–265.
23.Destache CJ. Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option. Prog Brain Res 2009; 180: 225-33.
[http://dx.doi.org/10.1016/S0079-24.6123(08)80012-X] [PMID: 20302837]
25.Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev 2010; 62(4-5): 478-90.
[http://dx.doi.org/10.1016/j.addr.2009.11.018]
26.[PMID: 19913579]
27.Khan I, Saeed K, Khan I. Nanoparticles: properties, application, and toxicities Arabian Journal of Chemistry 2017; 5-011. [http://dx.doi.org/10.1016/j.arabjc.2017.05.011
28.das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 2010; 62(4-5): 458-77. [http://dx.doi.org/10.1016/j.addr.2009.11.017] [PMID: 19914314]
29.Pattni BS, Chupin VV, Torchilin VP. New developments in lipo-somal drug delivery. Chem Rev 2015; 115(19): 10938-66.
[http://dx.doi.org/10.1021/acs.chemrev.5b00046]
30.[PMID: 26010257
31.Mamo T, Moseman EA, Kolishetti N, et al. Emerging nanotech-nology approaches for HIV/AIDS treatment and prevention. Na-nomedicine 2010; 5(2): 269-85.
32.[http://dx.doi.org/10.2217/nnm.10.1] [PMID: 20148638]
33.Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9(8): 615-27.
[http://dx.doi.org/10.1038/nrd2591]
34.[PMID: 20616808]
35.Wang AZ, Gu F, Zhang L, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008; 8(8): 1063-70.
36.[http://dx.doi.org/10.1517/14712598.8.8.1063] [PMID: 18613759]
37.Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011; 6(4)e18270 [http://dx.doi.org/10.1371/journal.pone.0018270] [PMID: 21483687]
38.Parboosing R, Maguire GEM, Govender P, Kruger HG. Nanotech-nology and the treatment of HIV infection. Viruses 2012; 4(4): 488-520.
39.[http://dx.doi.org/10.3390/v4040488] [PMID: 22590683]
40.Parboosing R, Maguire GEM, Govender P, Kruger HG. Nanotech-nology and the treatment of HIV infection. Viruses 2012; 4(4): 488-520.
41.[http://dx.doi.org/10.3390/v4040488] [PMID: 22590683]
42.Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic. nanoparticles. Adv Drug Deliv Rev 2010; 62(11): 1052-63.
43.[http://dx.doi.org/10.1016/j.addr.2010.08.004] [PMID: 20709124
44.Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–347.
45.Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. Nature. 1999;401(6756):874–875.
46.Marsden MD, Zack JA. Eradication of HIV: Current challenges and new directions. J Antimicrob Chemother. 2009;63(1):7–10.
47.Sax PE, Cohen CJ, Kuritzkes DR. HIV Essentials. Physicians' Press; Royal Oak, MI, USA: 2007.
48.Lamers SL, Salemi M, Galligan DC, et al. Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One. 2009;4(3):E5065.

49.McGee B, Smith N, Aweeka F. HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin Trials. 2006;7(3):142–153.
50.Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted peg-fmlf (nformyl-methionyl- leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res. 2007;24(11):2110–2119.
51.Nowacek A, Gendelman HE. Nanoart, neuroAIDS and CNS drug delivery. Nanomed.
52.2009;4(5):557–574. [PMC free article]
53.Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human. monocytes/macrophages in vitro. J Drug Target. 2007;15(1):89–98.
54.Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta. 2007;1770(4):681– 686.
55.Dutta T, Garg M, Jain NK. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci. 2008;34(2–3):181–189.
56.Wan L, Zhang X, Pooyan S, et al. Optimizing size and copy number for PEG-FMLF (n-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug Chem. 2008;19(1):28–38.
57.Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol. 2008;18(2):203–217.
58.Pornillos O, Ganser-Pornillos BK, Kelly BN, et al. X-ray structures of the hexameric building block of the HIV capsid. Cell. 2009;137(7):1282–1292.
59.Friedman SH, Decamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL. Inhibition of the HIV-1 protease by fullerene derivatives – model-building studies and experimental- verification. J Am Chem Soc. 1993;115(15):6506–6509.
60.Bosi S, Da Ros T, Spalluto G, Balzarini J, Prato M. Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60] fullerene derivatives. Bioorg Med Chem Lett. 2003;13(24):4437–4440.
61.Kotelnikova RA, Bogdanov GN, Frog EC, et al. Nanobionics of pharmacologically active derivatives of fullerene c-60. J Nanopart Res. 2003;5(5–6):561–566.
62.Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg Med Chem Lett. 2005;15(15):3615–3618.
63.Troshina OA, Troshin PA, Peregudov AS, Kozlovskiy VI, Balzarini J, Lyubovskaya RN. Chlorofullerene c60cl6: A precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Org Biomol Chem. 2007;5(17):2783–2791.
64.Durdagi S, Supuran CT, Strom TA, et al. In silico drug screening approach for the design of magic bullets: A successful example with anti-HIV fullerene derivatized amino acids. J Chem Inf Model. 2009;49(5):1139–1143.
65.Tanimoto S, Sakai S, Matsumura S, Takahashi D, Toshima K. Chem Commun. 44. 2008. Target-selective photo-degradation of HIV-1 protease by a fullerene–sugar hybrid; pp. 5767– 5769.
66.Blanzat M, Turrin CO, Aubertin AM, et al. Dendritic catanionic assemblies: In vitro anti- HIV activity of phosphorus-containing dendrimers bearing gal beta (1)cer analogues. Chembiochem. 2005;6(12):2207–2213.
67.Wang W, Guo ZP, Chen Y, Liu T, Jiang L. Influence of generation 2–5 of pamam dendrimer on the inhibition of tat peptide/tar rna binding in HIV-1 transcription. Chem Biol Drug Des. 2006;68(6):314–318.
68.Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV1.J Nanobiotechnology. 2005; 3:6.
69.Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM. Silver nanoparticles fabricated in hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun. 2005;(40):5059–5061.

70.Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C.
Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc.
2008;130(22):6896–6897.
71.Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol.
2007;25(12):1444–1454.
72.Haasnoot J, Westerhout EM, Berkhout B. Rna interference against viruses: strike and
counterstrike. Nat Biotechnol. 2007;25(12):1435–1443.
73.Li M, Rossi JJ. Lentiviral vector delivery of siRNA and shrna encoding genes into
cultured and primary hematopoietic cells. Methods Mol Biol. 2008; 433:287–299.
74.Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy.
Gene Ther. 2006;13(6):553–558.
75.Li M, Li H, Rossi JJ. RNAI in combination with a ribozyme and tar decoy for
treatment of HIV infection in hematopoietic cell gene therapy. Ann NY Acad Sci.
2006; 1082:172–179.
76.Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary
hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV
shrna, anti-ccr5 ribozyme, and a nucleolar-localizing tar decoy. Mol Ther.
2005;12(5):900–909.
77.Lee SK, Dykxhoorn DM, Kumar P, et al. Lentiviral delivery of short hairpin RNAs
protects CD4 T cells from multiple clades and primary isolates of HIV. Blood.
2005;106(3):818–826.
78.Barnor JS, Miyano-Kurosaki N, Yamaguchi K, Abumi Y, Ishikawa K, Yamamoto N.
Lentiviral-mediated delivery of combined HIV-1 decoy tar and VIF siRNA as a single
rna molecule that cleaves to inhibit HIV-1 in transduced cells. Nucleosides Nucleotides
Nucleic Acids. 2005;24(5–7):431–434.
79.Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV
ribozyme in autologous CD34+ cells. Nat Med. 2009;15(3):285–292.
80.Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev.
2009;109(2):259–302.
81.Lundin KE, Simonson OE, Moreno PM, et al. Nanotechnology approaches for gene
transfer. Genetica. 2009;137(1):47–56.
82.Gao X, Kim KS, Liu DX. Nonviral gene delivery: What we know and what is next.
AAPS
83.J. 2007;9(1): E92–E104.
84.Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific
genetic interference by double-stranded RNA in caenorhabditis elegans. Nature.
1998;391(6669):806–811.
85.Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA
delivery. Nat Rev Drug Discov. 2009;8(2):129–138.
86.Berkhout B, ter Brake O. Towards a durable rnai gene therapy for HIV-AIDS. Expert
Opin Biol Ther. 2009;9(2):161–170.
87.Davis ME. The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm.
2009;6(3):659– 668.
88.Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a
peptide transduction domain-dsrna binding domain fusion protein. Nat Biotechnol.
2009;27(6):567–571.
89.Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering
rnas via cell-surface receptors. Nat Biotechnol. 2005;23(6):709–717.
90.Liu Z, Winters M, Holodniy M, Dai H. Sirna delivery into human t cells and primary
cells with carbon-nanotube transporters. Angew Chem Int Ed. 2007;46(12):2023–2027.
91.Weber N, Ortega P, Clemente MI, et al. Characterization of carbosilane dendrimers as
effective carriers of siRNA to HIV-infected lymphocytes. J Control Release.
2008;132(1):55– 64.
92.Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1
infection in humanized mice. Cell. 2008;134(4):577–586.
93.Kumar P, Wu HQ, McBride JL, et al. Transvascular delivery of small interfering RNA
to the central nervous system. Nature. 2007;448(7149):39–43.

94.McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes B. The immune response during acute HIV78-1 infection: Clues for vaccine development. Nat Rev Immunol. 2009.
95.Pett SL. Immunotherapies in HIV-1 infection. Curr Opin HIV AIDS. 2009;4(3):188–193.
96.Gandhi RT, Walker BD. Immunologic control of HIV-1. Ann Rev Med. 2002; 53:149–172.
97.Cohen J. Building an HIV-proof immune system. Science. 2007;317(5838):612–614.
98.Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med. 2009;265(1):138–158.
99.Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Ann Rev Immunol. 2000; 18:767–811.
100. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2(3):151–161.
101. Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R, et al. Therapeutic AIDS vaccines. Curr Pharm Des. 2006;12(16):2017–2030.
102. Dorrell L, Williams P, Suttill A, et al. Safety and tolerability of recombinant modified vaccinia virus ankara expressing an HIV-1 gag/multiepitope immunogen. (MVA. HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine. 2007;25(17):3277–3283.
103. Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. Canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009;27(43):6088–6094.
104. Whiteside TL, Piazza P, Reiter A, et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic. human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2009;16(2):233–240.
105. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic cell immunotherapy: From ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7(10):790–802.
106. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26–34.
107. Hori Y, Winans AM, Huang CC, Horrigan EM, Irvine DJ. Injectable dendritic cell- carrying alginate gels for immunization and immunotherapy. Biomaterials. 2008;29(27):3671–3682.
108. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly (d,l-lacticco-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22(19):2406–2412.
109. Aline F, Brand D, Pierre J, et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic pla nanoparticles induce enhanced cellular immune. responses against HIV-1 after vaccination. Vaccine. 2009;27(38):5284–5291.
110. Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem. 2007;14(18):1911–1919.
111. Bass E, Feuer C, Warren M. Aids vaccine research and advocacy: An update. BETA. 2009;21(2):24–30.
112. Jefferys R. Vaccine failure is not a 'crises for HIV research. Nature. 2008;453(7196):719–720.
113. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455(7213):613–619.
114. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and t cell stimulation by dendritic cells. Ann Rev Immunol. 2002; 20:621–667.
115. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol. 2005; 23:975–1028.
116. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory b cell development. Ann Rev Immunol. 2005; 23:487–513.
117. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomed. 2008;3(3):343–355.

118. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination.
Adv Drug Deliv Rev. 2009;61(2):140–157.
119. Sakaue G, Hiroi T, Nakagawa Y, et al. HIV mucosal vaccine: Nasal
immunization with gp160-encapsulated hemagglutinating virus of japan-liposome.
induces antigen-specific ctls and neutralizing antibody responses. J Immunol.
2003;170(1):495–502.
120. Singh SK, Bisen PS. Adjuvanticity of stealth liposomes on the
immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine. 2006;24(19):4161–4166.
121. Wagner A, Stiegler G, Vorauer-Uhl K, et al. One step membrane incorporation
of viral antigens as a vaccine candidate against HIV. J Liposome Res. 2007;17(3–
4):139–154.
122. Watson DS, Huang Z, Szoka FC., Jr All-trans retinoic acid potentiates the
antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid a.
Immunol Cell Biol. 2009 [PMC free article]
123. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat
Rev Immunol. 2006;6(12):930–939.
124. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the
neutralizing antibody problem. Nat Immunol. 2004;5(3):233–236.
Takeda K, Kaisho T, Akira S. Toll-like receptors. Ann Rev Immunol. 2003; 21:335–
376.
125. Fairman J, Moore J, Lemieux M, et al. Enhanced in vivo immunogenicity of
SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque
pilot study. Hum Vaccin. 2008;5(2)
126. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van
Nest G. Mf59. Design and evaluation of a safe and potent adjuvant for human vaccines.
Pharm Biotechnol. 1995; 6:277–296.
127. Copland MJ, Rades T, Davies NM, Baird MA. Lipid based particulate.
formulations for the delivery of antigen. Immunol Cell Biol. 2005;83(2):97–105.
128. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine
adjuvants. Vaccine. 2009;27(25–26):3331–3334.
129. Leung L, Srivastava IK, Kan E, et al. Immunogenicity of HIV-1 env and gag in
baboons using a DNA prime/protein boost regimen. AIDS. 2004;18(7):991–1001.
130. Brave A, Hinkula J, Cafaro A, et al. Candidate HIV-1 gp140δv2, gag and tat
vaccines protect against experimental HIV-1/MULV challenge. Vaccine. 2007;25(39–
40):6882–6890.
131. Burke B, Gomez-Roman VR, Lian Y, et al. Neutralizing antibody responses
to subtype b and c adjuvanted HIV envelope protein vaccination in rabbits. Virology.
2009;387(1):147– 156.
132. Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker
JR., Jr Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant
produces th1 polarized responses and neutralizing antibodies to primary HIV type 1.
isolates. AIDS Res Hum Retroviruses. 2008;24(2):271–281.
133. Ataman-Onal Y, Munier S, Ganee A, et al. Surfactant-free anionic pla
nanoparticles
134. coated with HIV-1 p24 protein induced enhanced cellular and humoral immune
responses in various animal models. J Control Release. 2006;112(2):175–185.
135. Lamalle-Bernard D, Munier S, Compagnon C, et al. Coadsorption of HIV-1
p24 and gp120 proteins to surfactant-free anionic pla nanoparticles preserves.
antigenicity and immunogenicity. J Control Release. 2006;115(1):57–67.
136. Guillon C, Mayol K, Terrat C, et al. Formulation of HIV-1 tat and p24 antigens
by pla nanoparticles or mf59 impacts the breadth, but not the magnitude, of serum and
faecal antibody responses in rabbits. Vaccine. 2007;25(43):7491–7501.
137. Miyake A, Akagi T, Enose Y, et al. Induction of HIV-specific antibody
response and protection against vaginal sHIV transmission by intranasal immunization
with inactivated sHIV-capturing nanospheres in macaques. J Med Virol.
2004;73(3):368–377.

138. Kawamura M, Wang X, Uto T, et al. Induction of dendritic cell-mediated
immune responses against HIV-1 by antigen-capturing nanospheres in mice. J Med
Virol. 2005;76(1):7–15.
139. Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to
dendritic cells using nanoparticles based on amphiphilic poly (amino acid) derivatives.
Biomaterials. 2007;28(23):3427–3436.
140. Wang X, Uto T, Akagi T, Akashi M, Baba M. Induction of potent CD8+ T-cell
responses by novel biodegradable nanoparticles carrying human immunodeficiency.
virus type 1 gp120. J Virol. 2007;81(18):10009–10016.
141. Wang X, Uto T, Akagi T, Akashi M, Baba M. Poly (gamma-glutamic acid)
nanoparticles as an efficient antigen delivery and adjuvant system: Potential for an
AIDS vaccine. J Med Virol. 2008;80(1):11–19.
142. Moss JA. HIV/AIDS Review. Radiol Technol 2013; 84(3): 247-67. [PMID:
23322863]
143. Ma X, Wang D, Wu Y, et al. AIDS treatment with novel anti-HIV compounds
improved by nanotechnology. AAPS J 2010; 12(3): 272-8.
[http://dx.doi.org/10.1208/s12248-010-9187-z]
[PMID: 20373061
144. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnol-ogy
applications for improved delivery of antiretroviral drugs to the brain. Adv Drug
Deliv Rev 2010; 62(4- 5): 503-17. [http://dx.doi.org/10.1016/j.addr.2009.11.020]
[PMID: 19914319]
145. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug
delivery technology. Saudi Pharm J 2018; 26(1): 64-70
146.
[http://dx.doi.org/10.1016/j.jsps.2017.10.012]
[PMID: 29379334]
147. Jayant R, Nair M. Nanotechnology for the treatment of NeuroA-IDS.
Journal of Nanomedicine Research 2016; 3(1): 00047.
148.
[http://dx.doi.org/10.15406/jnmr.2016.03.00047]
149. Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of
nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J
Immunol 2009; 183(1): 661-9.
150.
[http://dx.doi.org/10.4049/jimmunol.0900274]
[PMID: 19535632]
151. Destache CJ. Chapter 12- Brain as an HIV sequestered site: Use of
nanoparticles as a therapeutic option. Prog Brain Res 2009; 180: 225-33.
[http://dx.doi.org/10.1016/S0079-
152. 6123(08)80012-X] [PMID: 20302837]
153. Spudich SS, Ances BM. Central nervous system complications of HIV
infection. Top Antivir Med 2011; 19(2): 48-57. [PMID: 21868822]
154. Rao KS, Ghorpade A, Labhasetwar V. Targeting anti-HIV drugs to the
CNS. Expert Opin Drug Deliv 2009; 6(8): 771-84.
[http://dx.doi.org/10.1517/17425240903081705]
155. [PMID: 19566446

Cite this article as:
Parvin S., Bindal P., Tiwari H. and Chandrul K. K. (2024). Intervention and Treatment of HIV/AIDS through Nanotechnology. *Int. J. of Pharm. & Life Sci.,* 15(1): 3-13.

Source of Support: Nil
Conflict of Interest: Not declared
For reprints contact: ijplsjournal@gmail.com